Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?

Fabio Zattoni1*, Isabel Heidegger2, Veeru Kasivisvanathan3,4, Alexander Kretschmer5, Giancarlo Marra6, Alessandro Magli7, Felix Preissers, Derya Tilki8,9, Igor Tsaur11, Massimo Valerio12, Roderick van den Bergh13, Claudia Kesch14, Francesco Ceci15, Christian Fankhauser16 and Giorgio Gandaglia17 on behalf of the YAU Prostate cancer (PCa) working group

The role and timing of radiotherapy (RT) in prostate cancer (PCa) patients treated with radical prostatectomy (RP) remains controversial. While recent trials support the oncological safety of early salvage RT (SRT) compared to adjuvant RT (ART) in selected patients, previous randomized studies demonstrated that ART might improve recurrence-free survival in patients at high risk for local recurrence based on adverse pathology. Although ART might improve survival, this approach is characterized by a risk of overtreatment in up to 40% of cases. SRT is defined as the administration of RT to the prostatic bed and to the surrounding tissues in the patient with PSA recurrence after surgery but no evidence of distant metastatic disease. The delivery of salvage therapies exclusively in men who experience biochemical recurrence (BCR) has the potential advantage of reducing the risk of side effects without theoretically compromising outcomes. However, how to select patients at risk of progression who are more likely to benefit from a more aggressive treatment after RP, the exact timing of RT after RP, and the use of hormone therapy and its duration at the time of RT are still open issues. Moreover, what the role of novel imaging techniques and genomic classifiers are in identifying the most optimal post-operative management of PCa patients treated with RP is yet to be clarified. This narrative review summarizes most relevant published data to guide a multidisciplinary team in selecting appropriate candidates for post-prostatectomy radiation therapy.

Keywords: prostate cancer, adjuvant radiotherapy, salvage radiotherapy, biochemical recurrence, hormonal therapy, genomic classifiers
INTRODUCTION

The most common primary treatment for localized prostate cancer (PCa) is radical prostatectomy (RP) (1). Approximately one third of men managed with RP will experience biochemical recurrence (BCR) over a 10-year period (2), and the majority of these patients will eventually develop distant metastases and/or will die of PCa over time if left untreated (3). Postoperative radiotherapy (RT) represents an option in a multimodal setting in order to reduce the risk of experiencing distant metastases at follow-up. Of note, RT might be administered in an adjuvant (i.e., immediately after surgery in the absence of signs of recurrence) or salvage setting (i.e., at the time of biochemical recurrence, BCR). However, there has been poor consensus regarding the timing of post-operative RT. Previous prospective, randomized clinical trials showed that ART was associated with a reduced risk of recurrence in patients at risk (i.e., positive surgical margins, pT3 disease, pathologic grade group 4–5). However, their generalizability is limited by either late use of SRT or no use of post-RP prostate-specific antigen (PSA) monitoring or both (4–7). More recent randomized studies compared ART with early SRT for patients with an increasing PSA level after RP (early SRT) and provide data which might be applied to contemporary patients (8–10). However, how to select patient at risk of progression who more likely will benefit from a more aggressive treatment after RP in a multimodal setting, the exact timing of RT after RP, and the use of hormone therapy and its duration at the time of RT are still open issues. This is particularly true when considering the poor sensitivity of imaging techniques (transrectal US, CT, pelvic MRI, PET/CT, and PET/MRI with different radiopharmaceuticals) in asymptomatic patients with early BCR after RP. Moreover, molecular biomarkers in this setting have been poorly addressed so far and their use in the clinical practice is still limited (11).

This narrative review summarizes most relevant published data to guide a multidisciplinary team in selecting appropriate candidates for post-prostatectomy radiation therapy after the availability of new landmarks randomized studies.

EVIDENCE ACQUISITION

A collaborative non-systematic literature review identified recently published randomized and non-randomized studies where outcome data were collected (cut-off date February 6th 2021). The medical electronic data base PubMed was used. The identified studies represented the basis for a narrative review of the literature analyzing role of ART and SRT for BCR/PSA persistence (BCP) after RP.

EVIDENCE SYNTHESIS

Defining Patients at Risk After Radical Prostatectomy

Accurate risk characterization could result in an appropriate management of post-RP patients. However, the optimal post-operative approach to these patients is a subject of continuous debate because the risk definition after RP relies on clinical, pathological features and PSA kinetics. Furthermore, the choice of treatment (initial observation, ART, and/or ADT) should be tailored according to prognostic factors and/or risk stratification.

Up to one-third of patients treated with RP may have adverse pathologic features (12), defined as positive surgical margins, extra-prostatic extension, seminal vesicle invasion, and/or lymph node invasion and high Gleason score.

Only patients with at least two of the following pathologic features are at higher risk of cancer specific mortality and may significantly benefit from adjuvant treatment after RP: pathologic Gleason score ≥8, pT3/pT4 disease, and the presence of nodal disease (≥1) (13).

In the study of Abdollah et al. men with low-volume nodal disease (< 3 LNs), ISUP grade 2–5 and pT3–4 or R1, as well as men with 3 to 4 positive nodes were more likely to benefit from RT after surgery, while the other subgroups did not (14).

However, the level of evidence for the management of pN1 patients is still low (15).

The most sensitive and the only validated biomarker for disease persistence and recurrence remains PSA and PSA-based parameters (PSA doubling time and interval to PSA failure). Persistent PSA is defined in the majority of studies as detectable post-RP PSA of ≥0.1 ng/mL within 4 to 8 weeks of surgery and occurs in 5–20% of men after RP (16, 17).

It is likely the expression of persistent local disease or pre-existing metastases and reflect in worse outcomes when compared to men experiencing BCR (18). In highly selected patients with favorable pathologic characteristics PSA persistence might also indicate the presence of benign tissue left in situ during the procedure (19). On the other hand, persistent PSA represents one of the worst prognostic factors for risk of metastasis and death (18, 20) when associated with adverse pathologic features (21). In these patients, the use of SRT may improve survival, although available data from number of study does not allow yet to make any clear treatment decision (20, 22).

When considering BCR after RP, the threshold that best predicts further metastases is a PSA level of >0.4 ng/mL and rising (4). However, this value should not be considered as the best cut-off to start further treatments. With access to ultrasensitive PSA testing, a rising PSA level below this level might be a cause for concern. So far, several studies report different cutoffs for defining BCR after RP. Currently the most common BCR definition in studies and guidelines is based on two consecutive PSA values >0.2 ng/mL and rising, representing a more sensitive threshold to PSA progression. However, a first rise in PSA levels should not be used as the only landmark to start treatments. Although better oncologic outcomes were noticed when salvage treatment was delivered at lower PSA levels, the accurate timing of its administration depends on pathologic features, functional status, quality of life effects and patient’s preferences (23–25). Based on the idea that the patient group experiencing BCR is a heterogeneous group, the EAU guidelines suggested a new stratification which accounts for the factors previously described (excluded PSA persistence). This allows to stratify patients in two risk groups: the EAU low-risk BCR (PSA-DT >1 yr and pathological ISUP grade <4) and EAU high-risk BCR (PSA-DT <1 yr or pathological ISUP grade 4–5) group (26).
This novel BCR risk categories could be easily implemented in daily practice and could be precious in the decision-making for post-operative RT.

Timing of Radiotherapy After Radical Prostatectomy
The optimal timing of RT after RP is still debatable (27). Adjuvant treatment has the aim of decreasing the risk of relapse in men without evidence of disease persistence or recurrence after primary treatment when adverse pathologic features are present. On the contrary, SRT consists of the administration of additional therapies at the time of recurrence and represent a curative approach in men experiencing BCR or PSA persistence. The supporters of ART consider the prompt treatment to be more efficient with reduced risk of BCR and clinical recurrence, with acceptable toxicity. On the other hand, SRT may reduce exposure to unnecessary risks and toxicity (Figure 1). In addition, the impact of ART on survival remains controversial.

Seven randomized controlled trials have assessed the outcomes of ART after RP. These trials can be subdivided into two groups: (1) older trials such as the SWOG 8794 (5), EORTC 22911 (4), ARO 96-02 (6) and the FinnProstate Group trial (7) where timely SRT was not always used in the control arm; (2) modern trials such as RADICALS-RT (8), RAVES (9) and GETUG-17 (10) which mandated early SRT for PSA failure in the control arm (Table 1). Randomized trials testing the role of ART [SWOG 8794 (5), EORTC 22911(4), ARO 96–02 (6), FinnProstate Group trial (7)] provided level I evidence regarding the improvement of biochemical control (bPFS), however with no clear advantage in terms of metastasis-free survival (MFS) and overall survival (OS). A recent meta-analysis of published randomized trials evaluating ART detected a significant improvement over a 10-year period in clinical progression and presentation of metastases, especially in patients with positive margins (28). However, there is no evidence of improved OS. The toxicity deriving from immediate radiotherapy proved acceptable with only mild increase of genitourinary toxicity (urethral stenosis and urinary incontinence) and rectal toxicity (28). However, it should be emphasized that none of the above-mentioned studies was conducted to confront ART and SRT, the studies had small sample size cohorts for OS analysis and ~30% of the enrolled patients in the SWOG and EORTC trial have received SRT after initial radiotherapy and PSA persistence. On the contrary, there is an evidence that approximately 50% of patients enrolled in these studies did not experience BCR. Thus, the administration of ART in up to half of patients with adverse pathologic characteristics at RP would represent an overtreatment and would expose patients to treatment-related side effects without oncologic benefits.

The FinnProstate Group trial (7) was conducted using higher radiation dose, modern technique and adequate follow-up on one hand, but on the other hand the study had a small sample size with about 50% of patients enrolled in both arms of the trial who had initial PSA < 0.2 ng/ml. The trial included patients with pT2 positive surgical margins or pT3a (no pT3b) and showed that 40% of the patients developed biochemical progression. The main advantage of ART in terms of BCR was observed in patients with pT2 or positive surgical margins. Most patients who did not receive ART developed metastatic disease; ART was associated with negligible genitourinary toxicity. The most interesting fact is that patients with BCR who did not undergo ART received SRT at a median PSA of 0.7 ng/ml (late SRT) and 75% of these patients had no evidence of disease at last follow-up. This might confirm a certain effectiveness of late SRT in patients with low-risk factors.

The probability of success of SRT is conditioned by several risk factors for disease progression: pre-SRT PSA values, GS > 7, seminal vesicles invasion, PSA-DT < 10–12 months, and negative surgical margins. As for PSA values, an increase of 0.1 ng/ml is followed by a loss of 2.6% of bPFS, with a level 2a evidence for initiating SRT at the lowest possible PSA (29). The authors of the study also suggest that a rising post-operative PSA > 0.05 ng/mL might be a reliable indicator of biochemical failure, which justifies the initiation of SRT before PSA reaches a level of >0.2 ng/mL. A very early administration of SRT (PSA < 0.2 ng/mL) seems to be more efficient than the early SRT (eSRT) (0.2 ng/mL < PSA < 0.5 ng/mL) or late SRT (PSA > 0.5–1 ng/mL), particularly in presence of multiple risk factors (pT3b–T4, negative surgical margins, GS > 7) (23). All studies that retrospectively confronted ART vs. SRT, showing benefit of ART, present several biases, such as “lead-time bias,” difficult to remove even with sophisticated statistical techniques. Another limitation of the studies, both randomized and non-randomized, is that they refer to data gathered in an era where conventional imaging was not able to assess the presence of disease. Furthermore, there are other points that need to be clarified in order to optimize the use of post-operative RT: total radiation dose, pelvic lymph-node irradiation, combination with hormone therapy.

The three more recent randomized trials (RADICALS-RT, GETUG-AFU 17, and RAVES) evaluated the optimal timing between surgery and start of post-operative RT. Despite some differences such as patient selection, trigger PSA levels for SRT (PSA 0.1 ng/ml in RADICALS; PSA 0.2 ng/ml for other two studies), study design and primary endpoint, their objective was to compare ART and eSRT. RADICALS-RT (8) randomly assigned 1,396 patients at risk for progression to ART or SRT for PSA progression. The primary outcome of the study was freedom from distant metastases. The RADICALS-RT authors reported 5-year biochemical progression-free survival of 85% for patients in the ART group and 88% for those in the SRT group [hazard ratio (HR) 1.10, 95% CI 0.81–1.49; p = 0.56] after a median follow-up of 4.9 years. Thus, the authors concluded that an observation policy with PSA controls and SRT in case of PSA progression should be the standard of care after RP. However, this study might be underpowered for patients with a high risk for progression, and a potential benefit of ART may be underestimated by including many patients with favorable risk disease. Interestingly, the presence of lymph node invasion at final pathology represented an exclusion criterion (8). GETUG-AFU 1710 (10) randomized trial aimed to compare ART vs. eSRT after RP combined with short-term ADT in nearly all men. The results of the study suggest that there is no benefit for event-free survival in patients assigned to ART compared with patients assigned to SRT. However, ART can delay time to progression and fewer men had undergone SRT compared with ART. The RAVES study (9) was designed to assess whether freedom from

Frontiers in Surgery | www.frontiersin.org 3 July 2021 | Volume 8 | Article 691473

Zattoni et al. The Role of ART and SRT for BCR After RP
biochemical progression with SRT was non-inferior to ART in patients with extra-prostatic extension, seminal vesicle invasion, or positive surgical margins. HRs favoring SRT in the high-risk subgroups including seminal vesicle invasion and Gleason score of 8–10 in the RAVES study can be explained by a later time observation of PSA progression in the SRT group than in the ART group.

The ARTISTIC collaborative meta-analysis and systematic review (30) was prospectively designed before the results from the three randomized clinical trials were known. It included 2,153 men from the three recent randomized trials and showed no evidence that event-free survival, which was driven by PSA progression, was improved with use of ART compared to SRT in men with localized or locally advanced PCa. Unfortunately, a final recommendation for the use of ART or SRT cannot be made yet. Several limitations of the available literature regarding the use of RT after RP, including lack of group uniformity in pathological risk factors; variability in PSA assay sensitivity and failure criteria; heterogeneity of RT dose and techniques; lack of studies with long follow-up duration; and the use of BCR as an outcome surrogate. Less information was available regarding metastatic recurrence, cancer-specific survival, and overall survival. The patient eligibility criteria for RADICALS-RT included patients who would not receive ART in typical clinical practice because of the low risk of recurrence. Observation of PSA progression in the salvage radiotherapy group occurs at a later time than in the adjuvant radiotherapy group, which can explain a better survivorship favoring SRT in the RADICALS-RT study and in the high-risk subgroups including seminal vesicle invasion and Gleason score ≥8 in the RAVES study. Finally, androgen-deprivation therapy (ADT) can delay time to progression and fewer men had undergone salvage compared with adjuvant radiotherapy in the RADICALS-RT and GETUG-AFU 17 trials—concurrent androgen-deprivation therapy with radiotherapy was used in some men in RADICALS-RT and nearly all men in GETUG-AFU 17 (27).

Postoperative RT may have a detrimental effect on functional outcomes, such as urinary continence and erectile function (31, 32). As such, the identification of the appropriate timing to initiate early SRT is of utmost importance to maximize cancer control and to avoid overtreatment. Recovery from urinary incontinence after RP occurs at a lower rate in patients after ART compared with SRT (31, 33). Concordant data from recent randomized studies showed worse late urinary incontinence or grade ≥3 urinary complications in patients in the SRT group (Table 1).

An algorithm try to summarize the treatment recommendations for the use of ART and SRT after RP (Figure 2). A final recommendation cannot be made yet because several questions are still open.

**ADT Plus Radiotherapy**

The use of ADT in conjunction with RT in the post-RP patient remains controversial. The main questions are whether, when, for how long and in what form ADT should be administered. Available literature has methodological weaknesses since there is a large difference in ADT protocols including when it was administered (e.g., pre-RP, pre-RT, during RT, post-RT), for how long (e.g., months vs. years), differences in RT techniques, targets, total dose administered and study oncologic outcomes.

There are some observational studies which compare RT with or without some form of hormone therapy or antiandrogenic
therapy (34–38). Four studies reported findings suggesting that patients who received ADT in combination with ART had better outcomes (bRFS), however only one study reported a statistically significant difference between the two groups. Specifically, Bastide et al. (34) reported that adjuvant ADT combined with RT after RP in patients with SVI resulted in a substantial benefit in 5 year bRFS.

In the retrospective study by Ost et al. (35) the addition of ADT to high dose ART showed significantly improved bRFS and clinical recurrence-free survival (cRFS). Around 30% of patients in RADICALS-RT reported receiving ADT with their post-operative radiotherapy. Although greater use of ADT might have improved outcomes, there is no evidence that it would have had a differential effect on the two arms of the trial. There are several observational studies evaluating post RP patients who received SRT alone compared to those who received SRT in combination with some type of ADT. Most of these suggest better outcomes for patients selected for SRT in combination with ADT.

Evidence from previous trials suggest that men receiving SRT benefit from the addition of ADT: RTOG 9601 showed an advantage in both, cancer-specific survival (CSS) and OS, for the use of 2 years bicalutamide (for all PSA values and for PSA > 1.5 ng/ml) and GETUG-AFU 16 showed an advantage in progression free survival and metastasis-free survival, for the use of 6 months Goserelin (39, 40). However, the offering of hormone therapy should be accompanied by a thorough discussion of the potential benefits and risks/burdens associated with its use in the SRT setting.

In a retrospective multicenter study including 525 patients reported that only in patients with more aggressive disease characteristics (pT3b/4 and ISUP grade >4, or pT3b/4 and a PSA level at early SRT of >0.4 ng/mL), the administration of concomitant ADT for more that 12 months resulted in a reduction in distant metastases (41). Likewise, in a retrospective study of 1,125 patients, three risk factors (stage ≥pT3b, Gleason score ≥8, and a PSA level at SRT of ≥5 ng/mL) for clinical recurrence were evaluated to determine which patients may benefit from long-term concomitant hormonal therapy (median ADT duration of 9 months). Their data suggest a significant effect of long-term ADT for patients with two or more adverse features.

### TABLE 1 | Summary of recently published randomized trials for ART.

| Trial design | Radicals-RT | GETUG-AFU 17 | Raves |
|--------------|-------------|--------------|-------|
| Patients randomized | Adjuvant: 697 | Adjuvant: 212 | Non-inferiority |
| Early salvage: 699 | Early salvage: 212 | Early salvage: 167 |
| Key eligibility criteria | One or more of: | - pT3a, pT3b, or pT4 | - Either positive margins |
| | - Positive margins; | - Extracapsular extension | - Or extracapsular extension |
| | - pT3a, pT3b, or pT4 | | |
| | - pT3a, pT3b, or pT4 | | |
| | - or Gleason 7–10 | | |
| | | | |
| Trigger for early salvage radiotherapy | PSA > 0.1 ng/mL and rising or three consecutive rising PSA levels still below 0.1 ng/mL | PSA ≥ 0.20 ng/mL and rising | PSA ≥ 0.20 ng/mL |
| Early salvage radiotherapy timing | ≤2 months of trigger PSA | As soon as possible after PSA relapse and before PSA of 1 ng/mL | ≤4 months of trigger PSA |
| Adjuvant radiotherapy timing | ≤6 months of radical prostatectomy | ≤6 months of radical prostatectomy | ≤4 |
| Use of hormone therapy | Participants could choose to enter a second randomisation to no hormones or hormones for 6 or 24 months’ duration; participants not randomized could receive hormone therapy off protocol | Yes, all patients | No |
| Primary endpoint | Freedom from distant metastases | Event-free survival | Freedom from biochemical progression |
| Urinary incontinence | Self-reported urinary incontinence was worse at 1 year for those in the adjuvant radiotherapy group (mean score 4.8 vs. 4.0; p = 0.0023) | Adjuvant: 116/212 (55%) | N/A |
| | | Early salvage: 35/212 (17%) | |
| Urinary disorder | Urethral stricture: Grade 3–4 within 2 years in 6% in the adjuvant radiotherapy group vs. 4% in the salvage radiotherapy group (p = 0.020) | - Urinary retention: | >grade 2 genitourinary toxicity rate (CTCAE*) |
| | | Adjuvant: 6/212 (3%) | Salvage radiotherapy (80/167 (54%) |
| | | Early salvage: 5/212 (2%) | Adjuvant (116/166 (70%) |
| | | - Micturition disorder | OR mixed 0.34, (95% CI 0.17–0.68; p = 0.0022) |
| | | Adjuvant: 2/212 (1%) | |
| | | Early salvage: 0 | |

CTCAE*, Adverse events were scored by clinicians per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.14. The CTCAE genitourinary domains included cystitis, urinary incontinence, urethral stricture or stenosis, urinary frequency or urgency, urinary retention, and haemorrhage (genitourinary). Gastrointestinal domains included diarrhoea, proctitis, haemorrhage (rectal), and incontinence (anal).
For patients with a single risk factor, short-term ADT (\(<12\) mo) was slightly beneficial whereas patients without risk factors did not show a benefit from concomitant ADT (42). As a limitation of the study, the indication for concomitant ADT, the type of drug administered, and the treatment duration were left at the discretion of the treating physician on the basis of individual patient characteristics.

**Imaging and Genetic Testing Before ART/SRT**

The decision to offer RT in recurrent PCa can be challenging. A proper patient selection is essential to ensure favorable outcomes. Patients usually undergo SRT without local imaging because SRT is usually delivered because of PSA values (ideally when the PSA level \(<0.5\) ng/mL), without histological conformation of local recurrence. In addition, the dose delivered to the prostatic fossa tends to be uniform since it has not been demonstrated that stereotaxic boost to the recurrence site during SRT improves the oncologic outcome with comparable patient reported genitourinary symptom burden (26, 43).

Modern imaging modalities may provide earlier and accurate identification of sites of recurrences in the pelvic area and thus result in change in RT planning of the irradiation field and improvement in oncological outcomes. In certain cases, PSA levels have limited correlation with tumor burden, and patients with poorly differentiated tumors may have metastatic disease in the absence of significantly elevated PSA levels.

Multiparametric MRI of the pelvis is accurate to correctly identify local recurrence in patients with BCR after RP (44, 45). However, its sensitivity in patients with PSA level \(<0.5\) ng/mL remains controversial (45–47). To promote standardization and reduce variations in the acquisition, interpretation, and reporting of local PCa recurrence recently has been proposed a codified method for image acquisition and assessment of PCa local recurrence using MRI after RP (PI-RR) (48). At the moment, whole-body MRI in detecting occult bone or LN metastases in the case of BCR requires further assessment.

After RP, transrectal ultrasound can occasionally show local recurrence as a hypoechoic nodular mass identified in the perianastomotic area. The detection rates in a subgroup of patients with rising PSA \(\leq0.5\) ng/mL are ranging between 28.1 and 73.0% (49, 50). The sensitivity however of anastomotic biopsies is low, especially for PSA levels \(<1\) ng/mL (51). The prostatic fossa is notoriously difficult to biopsy and MR-TRUS fusion-guidance may aid in the localization of targets compared to TRUS-guidance alone (52). One implication of accurately localizing recurrences is that it enables targeted boost radiotherapy to confirmed lesions which is thought to improve response (53).
At the moment, prostate-specific membrane antigen PET/CT has shown good potential in patients with BCR, even with PSA levels <0.5 ng/mL (54) with a detection rate around 33–45% (55). Promising results for PET/CT are coming from not only retrospective studies but also from recent prospective trials.

68Ga-PSMA-11 PET accuracy in a prospective multicenter trial have showed 84 to 92% positive predictive value, 75% overall detection rate increasing with PSA values (38% for <0.001, 57% for 0.5 to <1.0 ng/mL, 84% for 1.0 to <2.0 ng/mL, 86% for 2.0 to <5.0 ng/mL, and 97% for 5.0 ng/mL), a good inter-reader reproducibility and safety (56).

According to a systematic review and meta-analysis (57), for PSA categories 0–0.19, 0.2–0.49, 0.5–0.99, 1.0, and >2 ng/mL, the percentages of positive scans are 33, 46, 57, 82, and 97%, respectively.

In OSPREY prospective trial, the diagnostic performance of PSMA PET/CT was assessed to determine sites of metastatic PCa. In post-therapy men with suspected recurrent or metastatic disease, PSMA PET/CT demonstrated high sensitivity (>88%) and PPV (≥75%) in all sites of disease and across all PSA ranges (58). The use of a histopathologic biopsy as gold standard for all patients and a blinded, independent reader paradigm is a distinct feature of OSPREY study in establishing diagnostic performance.

In 208 patients with BCR (PSA ranging between 0.2 and 98.4 ng/mL) and negative standard imaging the performance of PSMA PET/CT (CONDOR study) was found to determine a correct localization rate of 84.8–87.0%. Interestingly 63.9% of evaluable patients had a change in intended management after PSMA PET/CT (59).

However, men with recurrent/persistent disease reflect different clinical settings and highly heterogeneous population, carrying different prognosis and different profiles of disease aggressiveness. Therefore, selecting the most suitable candidates for PSMA PET/CT is critical to optimize its use and to spare lower-risk patients by expensive and potentially unnecessary staging procedures. By identifying patients with high probability to result in positive PSMA PET/CT, suspicious PCa recurrence could be identified and treatment strategies adjusted accordingly. Nomogram might represent a comprehensive and useful tool in guiding physicians in the most appropriate use of PSMA PET/CT. Models include pathologic parameters (ISUP grade), biochemical characteristics (PSA, PSAdt, ongoing ADT, and time to relapse) and the clinical settings of PSA relapse. Nomogram may allows a smoother patient selection by the clinician, prior to imaging referral in comparison to the use of the PSA values only (60–62).

Sites of recurrence can be clarified by PSMA PET and disease localization may translate into management changes in >50% of patients with BCR (63). Thus, SRT may represent a future strategy in case of BCR where PSMA PET rules out metastatic disease.

In a recent systematic review and meta-analysis (64), PET/MRI seems to have a pooled detection rate of 80.9% (95% CI 73.0–86.9%). However, heterogeneity among the studies was very high. Interestingly, both Grubmuller et al. (65) and Hope et al. (66) reported a high detection rate for recurrent PCa even at very low PSA levels (<0.5 ng/mL). This may prompt changes in RT planning. It is worth noting that the term “PSMA PET” refers to several different radiopharmaceuticals and at present there are no conclusive data about comparison of such tracers. Little difference in terms of detection rate was revealed between the three most commonly used PSMA-radiotracers (68Ga-PSMA11, 18F-PSMA-1007, 18F-DCFPyl), which in turn showed clear superiority to choline and fluciclovine. In a network meta-analysis, 18F-PSMA-1007 is favored in all pairwise comparisons. However, there is currently insufficient evidence to favor any routinely used PSMA-radioligands over another owing to the limited evidence base and risk of publication bias (67).

For the future, new PET tracers and the extraction and quantification of MRI imaging features (radiomics) (68, 69) may guide future research in patients stratification into high potential responder (negative findings or recurrence confined to the prostate) and poor potential responder (positive nodes or distant disease) to SRT.

Genomic markers have been proposed as a complementary tool for risk stratification in patients with PCa. These markers capture genomic information specific to each patient’s tumor which is beyond routinely available clinical and pathologic characteristics (tumor stage, grade, PSA value). In the last decade, there has been heightened interest in exploring the utility of different genomic signatures that serve as prognostic markers of cancer control in patients newly diagnosed with localized PCa as well as in patients who have undergone RP. Several novel biomarkers have been introduced for the diagnostic (PHI®, 4K score, SelectMDx®, ConfirmMDx®, PCA3, MiPS, ExoDX®, mpMRI) and prognostic purpose (OncotypeDX GPS®, Prolaris®, ProMark®, DNA-ploidy, Decipher®) (70).

The most utilized test in the real world practice is Decipher, which has been shown to correlate with increased cumulative incidence of BCR, metastasis and PCa-specific mortality (70, 71).

A recent systematic review (11) evaluated the clinical effectiveness of the Decipher genomic classifier (GC) for men with PCa. The authors found consistent evidence that the test may help to identify which cancers are more or less aggressive.

Decipher GC is prognostic for long-term metastasis/survival and changes management of PCa in the post-RP setting. Results have been demonstrated in prospective and post-hoc analysis of randomized clinical trials. Furthermore, GC results predict benefit from receipt of treatment which in turn supports personalized treatment decision-making in post-RP patients.

In this particular setting, Decipher GC may guide ART or SRT after RP based on a discrete cut-off score. Moreover, in patients who have already harbored BCR, it can guide decisions regarding the need for early/multimodal SRT vs. SRT alone. Interestingly, patients with higher Decipher GC scores were found to have more metastatic lymph node involvement on PSMA PET-imaging in a study population with 48% of prostatectomy patients. These suggests that patients with GC high risk might benefit from more nodal imaging and treatment intensification (72).

The Decipher GC met high level evidence in post-prostatectomy setting for both Simon and AUA criteria (11). This said, the evidence supports a routine use in clinical situations that will change patient management.
CONCLUSION

The three most recent randomized trials RADICALS-RT, GETUG-AFU 17, and RAVES and the ARTISTIC metaanalysis all conclude that SRT may offer the opportunity to avoid, or at least postpone, radiotherapy and its associated side effects for many men with no obvious disadvantage to event-free survival.

However, in daily practice ART should be proposed to patients with PSA persistence, EAU high-risk group or to patients with seminal vesicle invasion, GS > 7. Whereas, in patients with undetectable PSA values, EAU low-risk group and no high-risk factors (e.g., pT2/SM + or pT3a/ SM + or GS<8 and nerve sparing surgery) SRT should be considered in cases when PSA levels rise (>0.2 ng/ml).

In the nearer future, molecular biomarkers, clinical and histopathological features and imaging diagnostics will have to be used in a complementary fashion in order to provide the best possible patient selection. Further prospective studies are needed to confirm these conclusions.

AUTHOR CONTRIBUTIONS

FZ and GG: conceived the study. FZ and AM: collected the data. FZ, GG, IH, VK, and AK: wrote the manuscript. GM, FP, CK, FC, and CF: interpretation of results. DT, IT, MV, and RB: supervision. All authors reviewed the results and approved the final version of the manuscript.

REFERENCES

1. Miller DC, Gruber SB, Holleben BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. (2006) 98:1826. doi: 10.1093/jnci/dj941
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year johns hopkins experience. Urol Clin North Am. (2001) 28:555–65. doi: 10.1016/S0094-0143(05)70163-4
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. (1999) 281:1591–7. doi: 10.1001/jama.281.17.1591
4. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjutant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. (2009) 181:956–62. doi: 10.1016/j.juro.2008.11.032
5. Bolla M, Van Poppel H, Tombal B, Vekemans K, Da Pozzo L, De Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. (2012) 380:2018–27. doi: 10.1016/S0140-6736(12)61253-7
6.Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjutant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. (2014) 66:243–50. doi: 10.1016/j.eururo.2014.03.011
7. Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, et al. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol. (2019) 76:586–95. doi: 10.1016/j.eururo.2019.07.001
8. Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. (2020) 396:1413–21. doi: 10.1016/S0140-6736(20)31553-1
9. Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjutant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. (2020) 21:1331–40. doi: 10.1016/S1470-2045(20)30456-3
10. Sargos P, Chabaud S, Latorzef I, Magné N, Benyoucef A, Sipiot S, et al. Adjutant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. (2020) 21:1341–52. doi: 10.1016/S1470-2045(20)30454-X
11. Jairath NK, D’Al Pra A, Vince R, Hess RT, Jackson WC, Tossonian JI, et al. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol. (2021) 79:374–83. doi: 10.1016/j.eururo.2020.11.021
12. Adamis S, Varkarakis IM. Defining prostate cancer risk after radical prostatectomy. Eur J Surg Oncol. (2014) 40:496–504. doi: 10.1016/j.ejso.2014.02.221
13. Abdollah F, Suardi N, Cozzarini C, Gallina A, Capitanio U, Bianchi M, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol. (2013) 63:998–1008. doi: 10.1016/j.eururo.2012.10.036
14. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. (2014) 32:3939–7. doi: 10.1200/JCO.2013.54.7893
15. Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, et al. Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review. Eur Urol Oncol. (2020) 3:565–81. doi: 10.1016/j.euo.2020.08.005
16. Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys. (2015) 91:288–94. doi: 10.1016/j.ijrobp.2014.09.039
17. Ploussard G, Staerman F, Pierrevelin J, Saad R, Beaulav J, Roupert M, et al. Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. J Urol. (2013) 190:1750–6. doi: 10.1016/j.juro.2013.04.073
18. Spratt DE, Dai DLY, Den RB, Troncoso P, Yousef K, Ross AE, et al. Performance of a prostate cancer genomic classifier in predicting metastasis in men with prostate-specific antigen persistence postprostatectomy. Eur Urol. (2018) 74:1077–14. doi: 10.1016/j.eururo.2017.11.024
19. Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, et al. Adjutant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. Eur Urol. (2017) 72:689–709. doi: 10.1016/j.eururo.2017.01.039
20. Preisser F, Chun FKH, Pompe RS, Heizne A, Salomon G, Graefen M, et al. Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes. Eur Urol. (2019) 818:674. doi: 10.1016/S1569-9056(19)30638-4
21. Rogers CG, Khan MA, Miller MC, Veltri RW, Partin AW. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer. (2004) 101:2549–56. doi: 10.1002/cncr.20637
22. Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, et al. Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur Urol. (2018) 73:436–44. doi: 10.1016/j.eururo.2017.07.026
23. Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, et al. Assessing the optimal timing for early salvage radiation therapy in patients
salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. (2019) 20:1740–9. doi: 10.1016/S1470-2045(19)30486-3

41. Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Collichia M, Bossi A, et al. Use of concomitant androgen deprivation therapy in patients treated with early salvage radiotherapy for biochemical recurrence after radical prostatectomy: long-term results from a large, multi-institutional series. Eur Urol. (2018) 73:512–8. doi: 10.1016/j.eururo.2017.11.020

42. Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, et al. Assessing the role and optimal duration of hormonal treatment in association with salvage radiation therapy after radical prostatectomy: results from a multi-institutional study. Eur Urol. (2019) 76:443–9. doi: 10.1016/j.eururo.2019.02.004

43. Beck M, Wust P, Barelkowski T, Kaul D, Thieme AH, Wecker S, et al. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical tomotherapy. Radiat Oncol. (2017) 12:125. doi: 10.1186/s13041-017-0866-2

44. Panebianco V, Barchetti E, Sciarra A, Musio D, Forte V, Gentile V, et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol. (2013) 23:1745–52. doi: 10.1007/s00330-013-2768-3

45. De Visschere PJ, Standaert C, Füttner J, Vileirs GM, Panebianco V, Walz J, et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol. (2019) 2:47–76. doi: 10.1016/j.euo.2018.09.010

46. Mertan F V, Greer MD, Borofsky S, Kabakus IM, Merino MJ, Wood BJ, et al. Multiparametric magnetic resonance imaging of recurrent prostate cancer. Top Magn Reson Imaging. (2016) 25:139–47. doi: 10.9789/1MR0.000000000000088

47. Coppola A, Platania G, Ticca C, De Mattia C, Borbola T, Palazzi MF, et al. Sensitivity of CE-MRI in detecting local recurrence after radical prostatectomy. Radil Med. (2020) 125:683–90. doi: 10.1111/1475-4143.13619

48. Panebianco V, Vileirs G, Weinreb JC, Türkerb B, Margolis D, Rüchenberg J, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-R:R): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Eur Urol Oncol. (2021). doi: 10.1016/j.euo.2021.01.003. [Epub ahead of print].

49. Connolly JA, Shinohara K, Presti JC, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology. (1996) 47:225–31. doi: 10.1006/uros.1996.0454

50. Scattoni V, Ruscigno M, Riber M, Montorsi F, De Pozzo L, Guazzoni G, et al. 68Ga-PSMA-11 PET/CT in prostate cancer patients with prostate-specific antigen rise after radical prostatectomy. Eur J Nucl Med Mol Imaging. (2018) 45:1644–54. doi: 10.1007/s00259-018-3922-7

51. Rouvière O, Vitry T, Lyonnet D. Imaging of prostate cancer. Part II–2020 update: treatment of relapsing and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis. Lancet. (2020) 396:1422–31. doi: 10.1016/S0140-6736(20)31952-8

52. Suvari N, Gallina A, Lista G, Gandaglia G, Abdollah F, Capitanio U, et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol. (2014) 65:546–51. doi: 10.1016/j.eururo.2013.01.027

53. Pearce A, Choo R, Danjoux C, Morton G, Loblaw DA, Szumacher E, et al. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. (2006) 65:78–83. doi: 10.1016/j.ijrobp.2005.11.041

54. van Stum MA, Aaronson NK, Pos FJ, Bosch JLHR, Kieffer JM, Tillier CN, et al. Impact of salvage radiotherapy on the timing of adjuvant radiotherapy and its timing on the health-related quality of life of prostate cancer patients. Eur Urol. (2016) 70:751–7. doi: 10.1016/j.eururo.2016.03.010

55. Bastide C, Bossi D, Lechevalier E, Bladou F, Barriol D, Brethueau D, et al. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? BJU Int. (2012) 109:525–30. doi: 10.1111/j.1440-1613.2011.10332.x

56. Ost P, Fonteyne V, Vileirs G, Lumen N, Oosterlinck W, De Meerleer G. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol. (2009) 56:669–77. doi: 10.1016/j.eururo.2009.05.041

57. Ost P, De Troyer B, Fonteyne V, Oosterlinck W, De Meerleer G. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. (2011) 80:1316–22. doi: 10.1016/j.ijrobp.2010.04.039

58. Pai HH, Eldridge B, Bishop D, Alexander A, Lesperance M, Blood P, et al. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? Can J Urol. (2009) 16:4541–52.

59. Ost P, Cozzarini C, De Meereel G, Fiorino C, De Potter B, Briganti A, et al. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys. (2012) 83:960–5. doi: 10.1016/j.ijrobp.2011.09.007

60. Shipley WU, Seiferheld W, Lukka HR, Major PP, Hney NM, Grignon DJ, et al. Radiation with or without androgen deprivation therapy in recurrent prostate cancer. N Engl J Med. (2017) 376:417–28. doi: 10.1056/NEJMoa1607529

61. Carrie C, Magné N, Burban-Provost P, Sargs P, Latorrife L, Lagrange JL, et al. Short-term androgen deprivation therapy combined with radiotherapy as
56. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68 Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer. *JAMA Oncol.* (2019) 5:856. doi: 10.1001/jamaoncol.2019.0996

57. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. *Eur Urol.* (2020) 77:403–17. doi: 10.1016/j.eururo.2019.01.049

58. Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Poulidiot F, Prosbst S, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate-specific membrane antigen PET/CT with 18 F-DCFPyL in prostate cancer patients (OSPREY). *J. Urol.* (2021) 206:52–61. doi: 10.1097/JPU.0000000000001698

59. Morris MJ, Rowe SP, Gorin MA, Saperstein L, Poulidiot F, Josephson DY, et al. Diagnostic performance of 18 F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONCORD Phase 3, multicenter study. *Clin Cancer Res.* (2021). doi: 10.1158/1078-0432.CCR-20-4573. [Epub ahead of print].

60. Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, Briganti A, et al. Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. *Eur J Nucl Med Mol Imaging.* (2020) 47:136–46. doi: 10.1007/s00259-019-04505-2

61. Bianchi L, Borghesi M, Schiavina R, Castellucci P, Ercole A, Bianchi FM, et al. Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA-PET/CT positivity in patients with prostate cancer recurrence and PSA <1 ng/ml external validation on a single institution database. *Eur J Nucl Med Mol Imaging.* (2020) 47:2100–5. doi: 10.1007/s00259-020-04696-x

62. Rauscher I, Diwle C, Haller B, Rischpler C, Heck MM, Gschwend JE, et al. Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen–ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. *Eur Urol.* (2018) 73:656–61. doi: 10.1016/j.eururo.2018.01.006

63. Fendler WP, Ferdinandus J, Czermin J, Eiber M, Flavell RR, Behr SC, et al. Impact of 68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. *J Nucl Med.* (2020) 61:1793–9. doi: 10.2967/jnumed.120.242180

64. Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, dal Moro F, et al. PET/MRI in prostate cancer: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging.* (2020) 48:859–73. doi: 10.1007/s00259-020-05025-0

65. Grubmuller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich TH, Haug AR, et al. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. *Clin Cancer Res.* (2018) 24:6300–7. doi: 10.1158/1078-0432.CCR-17-0768

66. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. *J Nucl Med.* (2017) 58:1956–61. doi: 10.2967/jnumed.117.192476

67. Alberts IL, Seide SE, Mengela C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. *Eur J Nucl Med Mol Imaging.* (2021). doi: 10.1007/s00259-021-05210-9. [Epub ahead of print].

68. Li L, Shiradkar R, Leo P, Alghohary A, Fu P, Tirumani SH, et al. A novel imaging based nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI. *EbioMedicine.* (2021) 63:103163. doi: 10.1016/j.ebiom.2020.103163

69. Yao S, Jiang H, Song B. Radiomics in prostate cancer: basic concepts and current state-of-the-art. *Chin J Acad Radiol.* (2020) 2:47–55. doi: 10.1007/s42058-019-00020-3

70. Kretschmer A, Tilki D. Biomarkers in prostate cancer – current clinical utility and future perspectives. *Crit Rev Oncol Hematol.* (2017) 120:180–93. doi: 10.1016/j.critrevonc.2017.11.007

71. Ross A, Johnson MH, Yousefi K, Davicioni E, Fedor HL, Glavari S, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. *Eur Urol.* (2016) 69:157–65. doi: 10.1016/j.eururo.2015.05.042

72. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, et al. Genomic risk predicts molecular imaging-detected metastatic nodal disease in prostate cancer. *Eur Urol Oncol.* (2019) 2:685–90. doi: 10.1016/j.euo.2018.11.002

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a shared affiliation with one of the authors FP at the time of review.

Copyright © 2021 Zattoni, Heidegger, Kassivisanathan, Kretschmer, Marra, Magli, Preisser, Tilki, Tsaur, Valerio, van den Bergh, Kesch, Ceci, Fankhauser and Gandaglia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.